Buscar
OPKO Health Inc
OPKAñadir a la lista de seguimiento
1.100USD
0.0000.00%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
830.60MCap. mercado
PérdidaP/E TTM
Más Datos de OPKO Health Inc Compañía
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Información de OPKO Health Inc
Símbolo de cotizaciónOPK
Nombre de la empresaOPKO Health Inc
Fecha de salida a bolsaNov 02, 1995
Director ejecutivoCruz (Tony F)
Número de empleados2997
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 02
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónOPK
Fecha de salida a bolsaNov 02, 1995
Director ejecutivoCruz (Tony F)
Ejecutivos de OPKO Health Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
--
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
--
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
--
--
Dr. Phillip Frost ,M.D.
Dr. Phillip Frost ,M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
--
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Charles W. Bishop, Ph.D.
Dr. Charles W. Bishop, Ph.D.
Chief Executive Officer of OPKO Renal
Chief Executive Officer of OPKO Renal
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
--
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
--
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
--
--
Dr. Phillip Frost ,M.D.
Dr. Phillip Frost ,M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Health Insurers
213.60M
57.69%
Client Payers
87.61M
23.66%
Government Payers
59.92M
16.18%
Patients
9.14M
2.47%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
436.06M
71.85%
Chile
62.38M
16.85%
Ireland
51.40M
13.88%
Spain
26.73M
7.22%
Mexico
25.52M
6.89%
Otro
-231.81M
-16.69%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Health Insurers
213.60M
57.69%
Client Payers
87.61M
23.66%
Government Payers
59.92M
16.18%
Patients
9.14M
2.47%
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.33%
Holbrook (Bruce C)
5.35%
Hsiao (Jane H)
4.39%
Frost Group, L.L.C.
4.31%
Otro
50.93%
Accionistas
Accionistas
Proporción
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.33%
Holbrook (Bruce C)
5.35%
Hsiao (Jane H)
4.39%
Frost Group, L.L.C.
4.31%
Otro
50.93%
Tipos de accionistas
Accionistas
Proporción
Corporation
38.33%
Investment Advisor
12.75%
Individual Investor
11.15%
Hedge Fund
7.72%
Investment Advisor/Hedge Fund
5.59%
Research Firm
0.64%
Bank and Trust
0.24%
Pension Fund
0.13%
Venture Capital
0.05%
Otro
23.40%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
451
236.82M
31.36%
-9.38M
2025Q4
453
195.81M
25.51%
-55.48M
2025Q3
457
208.31M
27.13%
-63.18M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Frost Gamma Investments Trust
222.46M
29.31%
+2.15M
+0.98%
Nov 21, 2025
Rubric Capital Management LP
47.79M
6.3%
--
--
Dec 31, 2025
Holbrook (Bruce C)
40.38M
5.32%
--
--
Feb 24, 2025
Hsiao (Jane H)
33.13M
4.36%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.97%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
31.23M
4.11%
+1.54M
+5.20%
Dec 31, 2025
GJN 2021 Trust
19.91M
2.62%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.62%
--
--
Feb 24, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.53%
State Street SPDR S&P Health Care Services ETF
0.46%
VanEck Israel ETF
0.14%
Humankind US Stock ETF
0.1%
iShares U.S. Healthcare Providers ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.53%
State Street SPDR S&P Health Care Services ETF
Proporción0.46%
VanEck Israel ETF
Proporción0.14%
Humankind US Stock ETF
Proporción0.1%
iShares U.S. Healthcare Providers ETF
Proporción0.1%
Goldman Sachs Innovate Equity ETF
Proporción0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.05%
iShares Russell 2000 Value ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
